Author: Bloom, Kristie; Maepa, Mohube Betty; Ely, Abdullah; Arbuthnot, Patrick
Title: Gene Therapy for Chronic HBV—Can We Eliminate cccDNA? Document date: 2018_4_12
ID: 0dr9eans_21
Snippet: Reconstituting the cytotoxic T-cell response against HBV holds great promise as a strategy for the immune-mediated clearance of the virus in chronic carriers. While engineered T-cells with chimeric T-cell receptors against HBV antigens have been developed, investigations are yet to progress beyond preclinical development of the technology [101] [102] [103] [104] [105] . DNA vaccines have the potential to induce strong antibody and T-cell-mediated.....
Document: Reconstituting the cytotoxic T-cell response against HBV holds great promise as a strategy for the immune-mediated clearance of the virus in chronic carriers. While engineered T-cells with chimeric T-cell receptors against HBV antigens have been developed, investigations are yet to progress beyond preclinical development of the technology [101] [102] [103] [104] [105] . DNA vaccines have the potential to induce strong antibody and T-cell-mediated immune responses and thereby clear chronic HBV infections (reviewed by [106] ). While studies exploring this strategy are few, inducing strong antiviral immunity with therapeutic vaccines in conjunction with cytokine-mediated stimulation of an immune response undoubtedly has potential for management of chronic hepatitis B.
Search related documents:
Co phrase search for related documents- antiviral immunity and chronic HBV infection: 1, 2
- antiviral immunity and chronic hepatitis: 1, 2, 3, 4
- antiviral immunity and dna vaccine: 1, 2
- antiviral immunity and great promise: 1
- antiviral immunity and HBV antigen: 1
- antiviral immunity and HBV infection: 1, 2, 3
- antiviral immunity and immune mediate: 1, 2
- antiviral immunity and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- antiviral immunity and preclinical development: 1, 2
- antiviral immunity and therapeutic vaccine: 1
- cell mediate and cytokine mediate: 1
- cell mediate and dna vaccine: 1
- cell mediate and immune mediate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- cell mediate and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- cell mediate and therapeutic vaccine: 1
- chronic carrier and HBV infection: 1, 2, 3
- chronic HBV infection and dna vaccine: 1
- chronic HBV infection and HBV antigen: 1, 2, 3, 4, 5, 6, 7, 8
- chronic HBV infection and HBV infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
Co phrase search for related documents, hyperlinks ordered by date